HIV vaccine - Crucell/IAVI/Beth Israel Deaconess Medical Center
Alternative Names: Ad26.ENVA.01 HIV vaccine; AdVac®/PER.C6® Technology-based HIV vaccine; HIV-vaccine-Ad26-ENVA-01; rAd26 vaccineLatest Information Update: 02 Oct 2021
At a glance
- Originator Crucell
- Developer Crucell; International AIDS Vaccine Initiative
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Parenteral, Injection)
- 23 Jul 2016 Crucell withdraws a phase I trial in HIV infections (Prevention, In volunteers) in Uganda prior to enrolment (PACTR201304000534302)
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention, In volunteers) in Kenya (Parenteral, Injection)